BANK VONTOBEL/CALL/ELI LILLY & CO/540/0.1/20.09.24 | Delayed Deutsche Boerse AG 01:54:32 2024-07-12 pm EDT | ||
| 38.14 EUR | +4.55% |
|
| Current month | +2.79% | ||
| 1 month | +18.36% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 38.14 | +4.55% |
| 24-07-11 | 36.48 | -3.49% |
| 24-07-10 | 37.8 | +3.50% |
| 24-07-09 | 36.52 | +2.24% |
| 24-07-08 | 35.72 | +0.73% |
Delayed Quote Deutsche Boerse AG
Last update July 12, 2024 at 01:54 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VM3L3L |
| ISIN | DE000VM3L3L0 |
| Date issued | 2023-10-06 |
| Strike | 540 $ |
| Maturity | 2024-09-20 (70 Days) |
| Parity | 10 : 1 |
| Emission price | 7.64 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 38.14 € |
|---|---|
| Lowest since issue | 8.29 € |
| Spread | 0.02 € |
| Spread % | 0.05% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
934.1
USD
Average target price
894.8
USD
Spread / Average Target
-4.21%
- Stock Market
- Warrants
- Warrant
